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Seven hundred and fifty-three patients with invasive squamous cell 
cancer of the cervix treated at the University of Michigan from 1970-1985 
are reported. These included stage IA 43, stage IB 345, stage IIA 27, stage 
IIB 163, stage IIIA 4, stage IIIB 113, stage IVA 32, stage IVB 26. The age 
ranged from 18 to 92 years with a mean of 49.9 years. Clinical character- 
istics included: nulliparity 11%, married 93%, obese 41%, hypertensive 
37%, diabetes 10%, smoking 50%, bleeding 76%. The cumulative five- 
year survival for all patients was 67% and this was influenced by the 
stage of disease: stage IA 98%, stage IB 89%, stage IIA 72%, stage IIB 
62%, stage III 37%, stage IVA 14%, stage IVB 4%. Patients with a well- 
differentiated tumor had an 85% survival rate while those with a poorly 
differentiated tumor had a 57% survival rate. The probabili ty of meta- 
static disease to lymph nodes corresponded to the stage of disease; stage 
I 17%, stage II 55%, stage III 70%, stage IV 81%. When lymph nodes 
were negative, the survival rate for all patients was 86% while those with 
positive nodes had a 33% survival rate. Factors which influenced survival 
in the univariate analysis included stage, node status, tumor grade, age, 
interval from previous pelvic examination, diabetes. Only stage, node 
status and tumor grade maintained significance in the multiple propor- 
tion hazard analysis. 
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Carcinoma of the cervix continues to be a leading 
cause of morbidity and mortality among gynecologic 
malignancies. Despite the institution of widespread 
cytologic screening, this remains the third most 
common gynecologic malignancy diagnosed and the 
second leading cause of death among gynecologic 
malignancies in the USA. Among carcinomas of the 
cervix, squamous cell cancer remains the most com- 
mon pathologic type. Authors have reported a 
number of factors that influence the prognosis in 
squamous cell cancer of the cervix. These include 
age, diabetes, smoking, parity, anemia, and extent of 
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disease (l-s). This study was undertaken to evaluate 
various prognostic factors related to survival for 
squamous cell carcinoma of the cervix. 
M a t e r i a l  a n d  m e t h o d s  
The clinical records, pathology reports, and tumor 
conference notes were reviewed for patients regis- 
tered at the University of Michigan Medical Center 
(UMMC) with a diagnosis of carcinoma of the cervix 
between 1970 and 1985. All patients having squamous 
cell carcinoma of the cervix were reviewed. Informa- 
tion was recorded for the clinical presentation, med- 
ical history, height, weight, oral contraceptive usage, 
treatment modality, tumor grade, and size of the cer- 
vical lesion. All patients were staged according to the 
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International Federation of Gynecology and Obstet- 
rics (FIGO) guidelines. We defined microinvasive car- 
cinoma (stage IA) where invasion did not exceed 3 mm 
and/or angiolymphatic invasion was not present. 
Patients with tumors that extended just into the 
parametrium were considered to have small stage IIB 
tumors while those that extended close, but not to the 
side wall, were considered to have large stage IIB 
tumors. Patients underwent  staging by the gyneco- 
logic oncologist and the radiation oncologist, with 
discussion at the Gynecologic Tumor Conference. 
Patients with stage I disease routinely underwent  IVP 
and chest X-ray. Patients with more advanced disease 
routinely underwent  chest X-ray, IVP, cystoscopy, 
barium enema, and sigmoidoscopy. Selected patients 
underwent  lymphangiogram and in the later years 
CAT scanning was routinely done. Radiation therapy 
during this time period was given with external beam 
and brachytherapy to give a combined total dose of 
8000-9000 Cgy to point A. Therapy utilized the split 
field technique where 1980 Cgy (180 Cgy per day) of 
whole pelvic radiation was given. This was followed 
by two intracavitary applications to a total of 7-8000 
mg h-  1. External beam with a midline block completed 
the therapy bringing the pelvic sidewall to 5000 Cgy. 
The original hematoxylin and eosin pathology slides 
were reviewed. When slides were unavailable, the 
microscopic features were recorded according to 
the original pathology report and review from the 
Gynecologic Tumor Conference. Well-differentiated 
tumors were defined when there was little nuclear 
pleomorphism and the cytologic atypia was not pro- 
nounced. Cells were generally large with abundant 
cytoplasm and a more normal nuclear to cytoplasmic 
ratio. In general the well-differentiated tumors pro- 
duced keratin, and mitotic figures were infrequent. 
Poorly differentiated tumors had pronounced nuclear 
pleomorphism, hyperchromatic nuclei and scant 
cytoplasm. Cells were smaller, mitoses were frequent 
and keratin formation was usually absent. Moder- 
ately differentiated tumors had intermediate charac- 
teristics. Patients with advanced lesions where 
brachytherapy could not be performed, received only 
external beam radiotherapy, 6500-7000 Cgy. All exter- 
nal beam therapy was given with cobalt 60 until 1981 
and then by linear accelerator (Clinac 18, 10-MV 
photons). Hysterectomy after radiation was not 
utilized. 
Statistical analysis was performed by the Univer- 
sity of Michigan, Department of Biostatistics, School 
of Public Health. Survival was plotted with the life 
table method described by Kaplan & Meier C6). The 
generalized Savage (Mantel-Cox) method was used to 
test differences in survival ~7-~). A Cox Model stepwise 
proportional hazard analysis was performed to com- 
pare the hazard for tumor-related deaths to potential 
risk factors. A two-way cross tabulation with X 2 
analysis was used to evaluate the various clinical 
features in relation to the stage of disease. 
Results 
During the time period 1970-1985, 753 patients with 
invasive squamous cell carcinoma of the cervix were 
treated. The number of patients by each stage in- 
cluded: stage IA 43 (5.7%); stage IB 345 (45.8%); stage 
IIA 27 (3.5%); stage IIB 163 (21.7%); stage IIIA 4 (0.2%); 
stage IIIB 113 (15.3%); stage IVA 32 (4.3%); stage IVB 
26 (3.5%). The age at time of diagnosis ranged from 18 
to 95 years with a mean age of 49.9 years. The mean 
age and range by stage was stage IA 39 yea~s (21-75 
years), stage IB 44.6 years (18-89 years), stage II 55 
years (25-93 years), stage III 56 years (25-92 years), 
stage IV 60.5 years (34-95 years). Clinical character- 
istics included: multiparity 89% (674/756); married 
93% (699/753); obese 41% (306/752); hypertensive 37% 
(281/752); diabetes 10% (76/752); oral contraceptive 
usage at the time of diagnosis for patients less than 
45 years old 26% (76/297); smoking 50% (352/699); 
presenting symptoms of bleeding 76% (567/748); pos- 
itive cytology at the time of diagnosis 82% (432/527). 
Three patients received the radiation sensitizer 
hydroxyurea. 
The node status was significantly influenced by the 
stage of disease. When the node status was available, 
the following percentages of positive nodes were 
found: stage 1 17% (45/261); stage I155% (43!78); stage 
III 70% (46/66); stage IV 81% (39/48). The presence of 
bilateral node metastases significantly (p = 0.00001) 
increased with the stage of disease: stage 17% (19/261); 
stage I127% (21/78); stage II145% (30/66); stage IV 71% 
(34/48). Clinical features that were significantly related 
to an advancing stage of disease included tumor 
grade, age of the patient over 60 years of age, obesity, 
hypertension, diabetes, symptom of bleeding, interval 
from cytologic examination. Factors which were not 
related to the stage of disease included parity, marital 
status, oral contraceptive usage less than 45 years 
old, smoking and positive cytology at the time of 
diagnosis. 
The cumulative five-year survival rate for all pa- 
tients with invasive squamous cell carcinoma exclud- 
ing microinvasion was 67% (Fig. 1). Survival rate was 
significantly influenced by stage (Fig. 2), stage IA 
98%, stage IB 89%, stage IIA 72%, stage IIB 62%, stage 
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Fig. 1. Overall survival for patients with invasive squamous cell 
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Fig. 2, Survival by stage of disease for patients with invasive 
squamous cell cancer of the cervix. 
III 36%,  s t a g e  I V A  14%,  s t age  IVB 4%.  S u r v i v a l  ra te  
w a s  i n f l u e n c e d  s ign i f i c an t l y  b y  the  t u m o r  g r a d e  (Fig. 
3). P a t i e n t s  w i t h  w e l l - d i f f e r e n t i a t e d  t u m o r  h a d  a n  85% 
c u m u l a t i v e  f i ve -yea r  s u r v i v a l  ra te  d e c r e a s i n g  to  57% 
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Fig. 3. Survival by tumor differentiation for all patients with 
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Fig. 4. Survival according to the presence or absence of 
metastatic disease to the lymph nodes for all patients with 
invasive squamous cell cancer of the cervix. 
for  t h o s e  w i t h  a p o o r l y  d i f f e r e n t i a t e d  t u m o r .  T h e  p r e s -  
ence  of  m e t a s t a t i c  d i s e a s e  to t he  l y m p h  n o d e s  s igni -  
f i can t ly  i n f l u e n c e d  s u r v i v a l  (Fig. 4). T h e r e  w a s  a n  86% 
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Fig. 5. Survival by tumor differentiation for patients with stage II 
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Fig. 6. Survival according to the presence or absence of 
metastatic disease to lymph nodes for stage II. 
survival rate for those with negative lymph nodes 
compared to 33% for those with positive lymph 
nodes. The interval from the previous cytology signi- 
ficantly influenced survival. Those who had a pelvic 
examination with cytology performed within one year 
had a 78% survival rate compared to 60% for those 
who had gone more than three years (p = 0.0001). The 
patients with diabetes had a 50% five-year survival 
rate compared to those without diabetes (p = 0.0005). 
Smoking did not significantly influence survival. In 
the Cox Model multiple proportion hazard analysis 
the significant predictors of survival included stage, 
lymph node status and grade of tumor. Factors found 
not to predict survival when other factors were in- 
corporated included diabetes, previous cytology, age 
and smoking history. 
A separate analysis was performed for patients with 
stage II disease. There was no significant difference in 
survival between stages IIA and IIB, and both groups 
were combined for further analysis. All patients with 
stage II had a combined cumulative five-year survival 
rate of 61%. The extension of disease did not signi- 
ficantly influence survival. Those with large tumors 
almost to the side wall had a 61% survival rate while 
those with tumors of smaller size had a 67% survival 
rate. The tumor differentiation was significant. Those 
with well-differentiated tumors had an 83% cumulat- 
ive five-year survival rate while those with moderate 
and poorly differentiated tumors had a 59% survival 
rate (Fig. 5). Regarding the stage II patients, the node 
status significantly influenced survival. Those with 
negative nodes had a 79% five-year survival rate. 
Those with three or fewer positive nodes had a 74% 
survival rate while those with more than three positive 
nodes had a 9% survival rate (Fig. 6). The status of 
the paraaortic nodes significantly influenced survival 
for those patients with positive pelvic nodes. When 
paraaortic nodes were negative, the cumulative five- 
year survival rate was 57%, and survival decreased to 
6% when these were positive (Fig. 7). During this time 
period, radiation therapy was not routinely given to 
the paraaortic area. Other factors that did not signific- 
antly influence survival in stage II disease included 
age, diabetes, hypertension and obesity. 
Patients who underwent  radiation therapy and 
failed with central and/or regional disease included: 
stage IB 1 (1%); stage IIB 4 (2.4%); stage IIIB 7 (6%). 
One patient with stage IB disease and one patient with 
stage IIB disease developed central failure after prim- 
ary radiation therapy and underwent  pelvic exentera- 
tion. Both are free of disease. Two patients with stage 
IIIB disease underwent  pelvic exenteration for central 
failure and both died of disease. Seven patients (3.2%) 
failed after radical hysterectomy. There were five 
patients with only a cuff recurrence and two were 
salvaged by radiation therapy. One of these five 
patients underwent  a pelvic exenteration after salvage 
radiation therapy and died of disease. 
Major complications requiring hospitalization or 
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Fig. 7. Survival according to the presence or absence of 
metastatic disease to the paraaortic lymph nodes for patients 
with stage II disease and positive pelvic lymph nodes. 
t reatment  delay are listed in Table 1. Significant com- 
plications not  listed included pyometra  8, and cystitis 
2. The fistula rate for stage I disease was 2.3% among 
patients treated by radical hysterectomy, and 1% for 
Table 1. Major radiation therapy complications by stage of 
disease and total for all stage I-III patients. (E/P-enteritis/ 
proctitis; SBO-small bowel obstruction; Fist-fistula). (Stage I 
patients treated by radiation only) 
Stage E/P SBO Fist No. % 
I 6 7 1 14/111 12.6 
II 4 3 7 14/163 8.5 
III 3 2 13 18/117 15.4 
Total 13 12 21 46/391 11.7 
Table 2. Fistula complications for patients treated with radiation 
therapy by stage of disease. (VV--vesicovaginal; RV--rectova- 
ginal; Combined--both recto and vesicovaginal) *8 patients had 
fistula at presention 
Stage VV RV Combined No. % 
I 1 1/111 1 
II 1 3 3 7/163 4.2 
III 2 7 4 13/117 11.1 
IV 7 2 9*/32 28 
those treated with radiation therapy. The vaginal 
fistulas by stage among patients treated by radiation 
are listed in Table 2. 
Discussion 
The results reported here reaffirm the prognostic 
value of clinical staging for squamous cell carcinoma of 
the cervix. Recently surgical staging for cervical cancer 
has been reported to be only of limited value due to 
the inability to control metastatic disease with our cur- 
rent therapy 19). Thus clinical staging will maintain its 
importance and remain an important  prognostic vari- 
able. The survival rate reported here is very similar to 
that  reported by Johnson et al.(2) with survival directly 
proportional to the stage of disease. In Johnson's  
report, 58% of patients had  a central or side wall re- 
currence which is much higher than the percentage 
reported here. The overall central failure rate in our 
patients was 9% and only five unde rwen t  exentera- 
tion. When patients failed treatment,  the vast majority 
of our patients had distant disease with isolated 
central disease playing only a limited role. The pelvic 
failure rate reported here is similar to that recently re- 
ported by Stehman 0°) from the GOG series utilizing 
the radiation sensitizer Hydroxyurea.  In our group of 
patients, however,  only a very small number  received 
radiation sensitizers. 
The influence of tumor grade in squamous cell 
cancer of the cervix has been reported to influence sur- 
vival 0'4). In this report the poorly differentiated 
squamous cell cancers had a decreased survival rate 
even when  accounting for the stage in the multiple 
proportional hazard analysis. These results are similar 
to those of Prempree who  reported a decrease in sur- 
vival rate in stage I from 79% for grade one to 43% for 
grade three, and in stage II from 58% for grade one 
to 44% for grade three. Prempree also reported that 
the patients with poorly differentiated tumors  had a 
higher percentage of metastatic disease (]) . 
The lymph node status appears to be a critical de- 
terminant  of survival. The survival is markedly de- 
creased stage for stage when  metastatic disease to the 
lymph node is present.  Additionally, as tumor stage 
progresses there is a higher percentage of node meta- 
stases and a higher propensi ty for bilateral node 
metastases. 
In our report a number  of factors in the univariate 
analysis were significant for predicting survival. How- 
ever, in the multiple proportion analysis, the factors 
that overwhelmingly influenced survival were the 
stage of disease, the lymph node status, and the tumor  
differentiation. Authors have reported the effects of 
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other  factors on  survival.  Kapp  et al. (4) utilizing a mul-  
tiple p ropor t ion  haza rd  analysis  repor ted  that  increas- 
ing age, diabetes ,  and  increasing par i ty  also p layed  a 
significant role in survival.  W h e n  eva lua ted  in our  
series, these variables did not  retain significance. 
Kucera et al. (3) r epor ted  that  in stage I and  II disease,  
smokers  had  a decreased  survival  c o m p a r e d  to non-  
smokers ,  bu t  we  did not  find this in our  g roup  of 
pat ients .  They  also repor ted  that  diabetes  affected 
survival  in stage I and  II. Authors  have  repor ted  that  
anemic  pat ients  have  a w o r s e n e d  prognos is  and  this 
could not  be eva lua ted  in our  series. All pat ients  were  
rout inely  t ransfused  to main ta in  hematocr i t s  above  
30, as it was  the ph i l o sophy  that  the radiat ion the rapy  
wou ld  be enhanced  by  this oxygen  carrying capacity. 
Stage IIA disease of the cervix can be t reated with  
radiat ion or radical surgery.  Our  prevai l ing philo- 
s o p h y  dur ing  this t ime per iod  was  that  radiat ion could 
bet ter  cover  these  larger lesions and  this was  the ther- 
apy  adminis tered .  Thus  only one  of 27 pat ients  un-  
de rwen t  radical hys te rec tomy.  The survival  rate for 
stage IIA repor ted  here  is ve ry  similar to that  r epor ted  
by  Perez ef al. (m. We cont inue  to em p l oy  radiat ion 
the rapy  as the prefer red  t r ea tment  for stage IIA dis- 
ease. In this repor t ,  the p resence  of a large stage IIB 
t u m o r  ex tending  a lmos t  to the side wall  did not  ad- 
verse ly  influence survival  c o m p a r e d  to the smaller  
s tage IIB tumor .  
Advanced  stage III disease is accompan ied  a lmost  
a lways  by  disease to the sidewall.  It is rare to have  
cervical cancer in the lower  third of the vagina  wi thou t  
extensive central  disease ex tending  to the sidewall.  In 
our  report ,  only  four pat ients  were  stage IIIA, at test ing 
to the rarity of this clinical stage. The 0.4% reported here  
is similar to the 1.5% repor ted  by  Cardinale  (12). Our  
survival  rate of 50% in stage IIIA is similar to the 58% 
survival  rate in 17 pat ients  r epor ted  by  Cardinale.  
The prognos i s  for s q u a m o u s  cell cancer of the cervix 
is inf luenced by  the extent  of disease and  the p resence  
of metas ta t ic  disease to regional  l y m p h  nodes .  The 
greates t  challenge lies in p reven t ion  and  earlier 
diagnosis  pr ior  to advanced  stage disease.  
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